Eledon Pharmaceuticals (ELDN) Gains from Investment Securities (2013 - 2026)
Eledon Pharmaceuticals (ELDN) reported Gains from Investment Securities of $19.0 million for Q1 2026, up 288.49% on a YoY basis from $4.9 million in Q1 2025, and down 17.28% quarter-over-quarter from $22.9 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals has reported Gains from Investment Securities for 8 years, with the latest figure at $19.0 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 288.49% year-over-year to $19.0 million; the trailing twelve-month figure through Mar 2026 stood at $29.0 million (up 226.4% YoY), and the FY2025 full-year result was $5000.0, down 98.84% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $19.0 million, down from $22.9 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $52.3 million in Q4 2024, with the low at -$96.4 million in Q3 2024.
- Historically, Gains from Investment Securities has averaged $757750.0 across 3 years, with a median of $9.2 million in 2025.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities slumped 139.31% — and 2026, when it surged 288.49%.
- Eledon Pharmaceuticals' Gains from Investment Securities stood at $52.3 million in 2024, then tumbled by 56.14% to $22.9 million in 2025, then retreated by 17.28% to $19.0 million in 2026.
- The last three Gains from Investment Securities figures came in at $19.0 million (Q1 2026), $22.9 million (Q4 2025), and -$564000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Eledon Pharmaceuticals | 401.35 Mn | 185.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.96 Mn |
| Mar 31, 2026 | 18.96 Mn |
| Dec 31, 2025 | 22.92 Mn |
| Dec 31, 2025 | 22.92 Mn |
| Sep 30, 2025 | -564,000.00 |
| Sep 30, 2025 | -564,000.00 |
| Jun 30, 2025 | -12.29 Mn |
| Jun 30, 2025 | -12.29 Mn |
| Mar 31, 2025 | -10.06 Mn |
| Mar 31, 2025 | -10.06 Mn |
| Dec 31, 2024 | 52.26 Mn |
| Dec 31, 2024 | 52.26 Mn |
| Sep 30, 2024 | -96.44 Mn |
| Sep 30, 2024 | -96.44 Mn |
| Jun 30, 2024 | 31.27 Mn |
| Jun 30, 2024 | 31.27 Mn |
| Dec 31, 2017 | -18,000.00 |
| Dec 31, 2017 | -18,000.00 |
| Dec 31, 2016 | -11,000.00 |
| Dec 31, 2016 | -11,000.00 |